Avigen to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
March 30 2006 - 9:00AM
PR Newswire (US)
ALAMEDA, Calif., March 30 /PRNewswire-FirstCall/ -- Avigen, Inc.
(NASDAQ:AVGN) a biopharmaceutical company developing innovative
therapies for the treatment of neurological conditions, announced
today that President and Chief Executive Officer Kenneth Chahine,
Ph.D., J.D., will present at the CIBC World Markets Annual
Biotechnology & Specialty Pharmaceuticals Conference. Avigen
will conduct a live webcast of Dr. Chahine's presentation at the
Millennium Broadway Hotel in New York City on Wednesday, April 5,
2006 from 1:15-1:45 pm EDT. To access the webcast over the
Internet, please go to http://www.avigen.com/ . A rebroadcast of
the presentation will be available shortly after the conclusion of
the session and remain available until May 5, 2006. The replay may
be accessed over the Internet at http://www.avigen.com/ . About
Avigen Avigen is a biopharmaceutical company focused on unique
small molecule therapeutics and biologics to treat serious
neurological disorders, including neuropathic pain and
neuromuscular spasm and spasticity. Avigen's strategy is to
complete the requirements of clinical develop for each of the
candidates in its product pipeline, and continue to look for
opportunities to expand its pipeline through a combination of
internal research, acquisitions, and in- licensing, with the goal
of becoming a fully integrated commercial biopharmaceutical company
committed to its small molecule and biologics neurology products.
The company currently has in development AV650 for neuromuscular
spasm and spasticity and two candidates for neuropathic pain, AV411
and AV333. Additionally, the company has in development a compound
for the treatment of multiple bleeding disorders, including
hemophilia A and B, AV513. For more information about Avigen,
consult the company's website at http://www.avigen.com/ . Statement
under the Private Securities Litigation Reform Act This advisory
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The
forward-looking statements in this advisory include statements
addressing the following subjects: Avigen, Inc.'s (the "Company")
expected date and time for the Company's presentation at the
Millennium Broadway Hotel in New York City on Wednesday, April 5,
2006. The time and date for the presentation are subject to change
due to unforeseen factors. The Company's belief that it will be
able to expand its pipeline through internal research,
acquisitions, and/or in- licensing, and its belief that it will be
able to develop, commercialize or obtain value from its current
drug candidates for any indication. These statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected in these forward-looking
statements. These risks and uncertainties include, among others,
the fact that development of small molecule therapeutics and other
therapeutic discovery and development is a time- and
resource-intensive process, which may result in the expenditure of
a significant amount of time and resources with no marketable
product resulting from the effort. Other risks and uncertainties
relating to Avigen are detailed in reports filed by Avigen with the
Securities and Exchange Commission, including Avigen's Annual
Report on Form 10-K for the period ended December 31, 2005, under
the caption "Risk Factors" in Item 1 of Part 1A of that report,
which was filed with the SEC on March 16, 2006. DATASOURCE: Avigen,
Inc. CONTACT: Michael Coffee, Chief Business Officer of Avigen,
Inc., +1-510-748-7372, or Web site: http://www.avigen.com/
Copyright
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Jul 2023 to Jul 2024